BIOXYTRAN, INC.: 10-K filed 2025-04-03
What BIOXYTRAN, INC. reported in its annual report filed 2025-04-03 (fiscal FY 2024): 27 published measures, 55 facts as tagged in accession 0001641172-25-002614.
This filing
- Form
- 10-K (annual report)
- Filed
- 2025-04-03
- Fiscal period
- fiscal FY 2024
- Accession
- 0001641172-25-002614 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOXYTRAN, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 138,694 | USD | |
| At 2023-12-31 | 139,382 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 1,930,642 | USD | |
| At 2023-12-31 | 3,244,238 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -2,366,681 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -4,472,525 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -55,737 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -775,375 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 63,000 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 550,361 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -28,195 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -44,301 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | -18,921,168 | USD | |
| At 2023-12-31 | -15,699,327 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 138,598,691 | shares | 366 |
| 2023-01-01 to 2023-12-31 | 133,973,352 | shares | 365 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 138,598,691 | shares | 366 |
| 2023-01-01 to 2023-12-31 | 133,973,352 | shares | 365 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -0.02 | USD/shares | 366 |
| 2023-01-01 to 2023-12-31 | -0.03 | USD/shares | 365 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -0.02 | USD/shares | 366 |
| 2023-01-01 to 2023-12-31 | -0.03 | USD/shares | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -2,223,068 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -3,800,212 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 5,154 | USD | |
| At 2023-12-31 | 26,086 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 1,930,642 | USD | |
| At 2023-12-31 | 3,244,238 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 133,540 | USD | |
| At 2023-12-31 | 113,296 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 2,223,068 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 3,800,212 | USD | 365 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 112,337 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 1,149,209 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 86,782,908 | shares | |
| At 2023-12-31 | 144,642,333 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | 16,999,279 | USD | |
| At 2023-12-31 | 13,085,715 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-12-31 | -1,791,948 | USD | |
| At 2023-12-31 | -3,104,856 | USD | |
| At 2022-12-31 | -3,296,975 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -2,380,005 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -4,562,783 | USD | 365 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -2,380,005 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -4,562,783 | USD | 365 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 1,167,502 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 1,403,324 | USD | 365 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 7,950 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 8,285 | USD | 365 |
Nonoperating interest expense
Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 84,240 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 193,191 | USD | 365 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | -156,937 | USD | 366 |
| 2023-01-01 to 2023-12-31 | -762,571 | USD | 365 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-12-31 | 164,447 | USD | 366 |
| 2023-01-01 to 2023-12-31 | 52,425 | USD | 365 |
Inspect the source
- Entity
- BIOXYTRAN, INC. / CIK 0001445815
- Captured
- 2026-09-20T09:04:34.317Z
- SEC response SHA-256
ae0d4cef36d6da3515a86f5d7ed5d620c87a101690fb1595784dc546884770e8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001445815.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))